Garsorasib vs Glecirasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Garsorasib · Anfangning

Marketed by Sino Biopharmaceutical and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05383898 · Phase 1/2 · completed

The study was a non-randomized, open-label, single-arm trial with no placebo or active comparator, despite enrolling 225 participants. Its primary outcomes included safety measures and overall response rate. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT07472478 (registry estimate)

Reported efficacy

Subject incidence of Dose-limiting toxicities (DLT) (through out the DLT period, approximately 21 days); Number of subjects participants with adverse events (Through study completion, approximately 3 years); antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation (Through study completion, approximately 3 years): IRC-confirmed ORR 50% (61 of 123 patients; 95% CI 41-59) (not_applicable)

Result source: NCT05383898

Glecirasib

Marketed by Allist Pharmaceuticals under a licence from Jacobio Pharmaceuticals

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05002270 · Phase 1/2 · completed

The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.

Next expected readout: March 2027 · NCT05288205 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGarsorasibGlecirasib
PFS, median—Trial running · NCT06300177—Trial running · NCT07601048
OS, median—Trial running · NCT06300177—Trial running · NCT07601048
ORR—Trial running · NCT06300177—Trial running · NCT07601048
Duration of response, median—Trial running · NCT06300177—Trial running · NCT07601048

PFS, median

Garsorasib
—Trial running · NCT06300177
Glecirasib
—Trial running · NCT07601048

OS, median

Garsorasib
—Trial running · NCT06300177
Glecirasib
—Trial running · NCT07601048

ORR

Garsorasib
—Trial running · NCT06300177
Glecirasib
—Trial running · NCT07601048

Duration of response, median

Garsorasib
—Trial running · NCT06300177
Glecirasib
—Trial running · NCT07601048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Glecirasib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Garsorasib
IRC-confirmed ORR 50% (61 of 123 patients; 95% CI 41-59) NCT05383898 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Garsorasib's landscape · Glecirasib's landscape